|
The history of AIDS (Acquired Immunodeficiency Syndrome), with timelines, photos, and links to resources on the Internet. Endeavoring to raise public awareness through understanding.
|
|
The History of AIDS: Timeline of the History of HIV/AIDS: 1998 1998 On January 8, 1998, FDA approved Glyde Dam Lollyes (Glyde USA, Inc., Redmond, WA 98052-4712) designed as a barrier for use while performing cunnilingus. When properly used, it may help reduce the risk of catching or spreading many Sexually Transmitted Diseases (STDs) such as syphilis, gonorrhea, chlamydia infections, gential herpes and HIV; however, it cannot completely eliminate the risk. On February 27, FDA cosponsored a 2 hour satellite broadcast from its television studio discussing the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. On May 6, 1998, FDA approved a virally inactivated, processed blood product (SD Plasma) manufactured from pooled human plasma that can serve as an alternative to fresh frozen plasma. The manufacturing process for this new product includes a solvent detergent procedure that inactivates some blood-borne viruses such as HIV. On May 28, 1998, FDA approved Cambridge Biotech HIV-1, a Human Immunodeficiency virus Type 1 (Western Blot) test with a new indication for urine specimen testing. On June 12, 1998, FDA approved Famvir (famciclovir/SmithKline Beechman) for the additional indication for the treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients at a dose of 500 mg twice daily. On July 22, 1998 FDA cosponsored a 2 hour satellite broadcast from its television studios discussing the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. On July 23, 1998, FDA issues guidance to manufacturers of Latex Condoms for Men - Information for 510(k) Premarket Notifications: Use of Consensus Standards for Abbreviated Submissions (pdf file) On August 26, 1998, FDA approved Vitravene Injection (fomivirsen sodium intravitreal injectable), Isis Pharmaceuticals, for the local treatment of cytomegalovirus (CMV) retinitis in patient with acquired immunodeficiency syndrome (AIDS) who are intolerant of or have a contraindication to other treatment(s) for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis. Approval Letter and Labeling. On September 17, 1998, FDA approved Sustiva (efavirenz), DuPont Pharmaceuticals, to treat HIV and AIDS. Approval Letter | Approved Labeling | Sustiva Consumer Information On December 17, 1998, FDA granted accelerated approval for Ziagen (abacavir), Glaxo Wellcome, to treat HIV-1 in adults and children. 1997 ...Last ||| Next... 1999 |